Abstracts tagged "juvenile idiopathic arthritis (JIA)"

Abstract Number: 164 • 2020 Pediatric Rheumatology Symposium
The Juvenile Idiopathic Arthritis-Associated IL2RA and IL6R Haplotypes Contain Enhancers Whose Functions Are Altered by JIA-Associated Genetic Variants
Kaiyu Jiang ¹, Yungki Park ², tao liu ³, Marc Sudman ⁴, Susan Thompson ⁵ and James Jarvis⁶, ¹University at Buffalo, Buffalo, ²University at Buffalo Jacobs School of Medicine & Biomedical Sciences, Buffalo, ³Roswell Park Cancer Institute, Buffalo, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, ⁵Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Cincinnati, ⁶University at Buffalo Jacobs School of Medicine, Buffalo
Background/Purpose: The JIA risk haplotypes, like those of other autoimmune diseases, are highly enriched for H3K4me1/H3K27ac histone marks, epigenetic features typically associated with functional enhancers.…
Abstract Number: 014 • 2020 Pediatric Rheumatology Symposium
Successful Validation of a Rapid Point-of-care Test for Serum Calprotectin (MRP8/14) as Biomarker in Juvenile Idiopathic Arthritis
Dirk Foell¹, Carolin Park ², Linda Ziegler ², Dirk Holziner ³, Kirsten Minden ⁴, Renato Cotti ⁵ and Jakob Weber ⁵, ¹University Hospital Muenster, Muenster, Nordrhein-Westfalen, Germany, ²University of Muenster, Muenster, Germany, ³University of Essen, Essen, Germany, ⁴Berlin, Germany, ⁵Buehlmann Laboratories, Schoenenbuch, Switzerland
Background/Purpose: Treat-to-target strategies are established for the therapeutic approach to patients suffering from juvenile idiopathic arthritis (JIA). Another proposed therapeutic concept in pediatric rheumatology involves…
Abstract Number: 086 • 2020 Pediatric Rheumatology Symposium
Advanced Multidisciplinary Care: A New Approach to Childhood Arthritis
Julia Brooks¹, Dorothy Adams ², Robin Hellweg ¹, Maggie Mercer ¹, Joni Shair ², Dwaraka Veeramreddy ³, Aynsley Wennberg ¹ and Heinrike Schmeling ⁴, ¹Alberta Children's Hospital, Calgary, Alberta, Canada, ²Alberta Children's Hospital, Calgary, Canada, ³Alberta Children's Hospital/University of Calgary, Calgary, Canada, ⁴Alberta Children's Hospital/University of Calgary, Calgary, Alberta, Canada
Background/Purpose: Many patients are overwhelmed with the diagnosis of chronic childhood arthritis and require long-term treatments. Our objective was to develop a new, child and…
Abstract Number: 165 • 2020 Pediatric Rheumatology Symposium
A Massively Parallel Reporter Assay Screen of Genetic Variants on JIA Haplotypes Reveals Variants Associated with Altered Function of an Intergenic Enhancer in the HLA Class II Locus
Kaiyu Jiang ¹, tao liu ², Ryan Tewhey ³ and James Jarvis⁴, ¹University at Buffalo, Buffalo, ²Roswell Park Cancer Institute, Buffalo, ³Jackson Laboratories, Bar Harbor, ⁴University at Buffalo Jacobs School of Medicine, Buffalo
Background/Purpose: While genome-wide association studies have provided valuable information about genetic risk for juvenile idiopathic arthritis (JIA), we are still unable to determine the actual…
Abstract Number: 017 • 2020 Pediatric Rheumatology Symposium
MyD88 S209R-Mediated Immune Dysregulation in Mouse Models of Arthritis
Sufia Bakshi¹, Malika Waschmann ², Anders Lindstedt ², Emily Rominger ², Robert Colbert ³ and Keith Sikora ⁴, ¹National Institutes of Health, Bethesda, Maryland, ²National Institutes of Health, Bethesda, ³NIH/NIAMS, Bethesda, Maryland, ⁴National Institutes of Health Clinical Center, Bethesda, Maryland
Background/Purpose: MYD88 is a critical adaptor protein that connects Toll-like and IL-1 receptor signaling to activation of NF-kB. We previously reported a heterozygous de novo mutation in MYD88 (S222R)…
Abstract Number: 097 • 2020 Pediatric Rheumatology Symposium
A Pilot Randomized Controlled Trial of the iCanCope Pain Self-management Application for Adolescents with Juvenile Idiopathic Arthritis
Chitra Lalloo ¹, Lauren Harris ², Amos Hundert ², Roberta Berard ³, Joseph Cafazzo ⁴, Mark Connelly ⁵, Brian Feldman ², Kristin Houghton ⁶, Adam Huber ⁷, Ronald Laxer ⁸, Nadia Luca ⁹, Heinrike Schmeling ¹⁰, Lynn Spiegel ¹¹, Lori Tucker ¹², Quynh Pham ⁴, Cleo Davies-Chalmers ¹³ and Jennifer Stinson¹⁴, ¹The Hospital for Sick Children, Toronto, Ontario, Canada, ²The Hospital for Sick Children, Toronto, Canada, ³Children's Hospital London Health Sciences Centre, London, Canada, ⁴University of Toronto, Toronto, Canada, ⁵Kansas City, ⁶University of British Columbia - Vancouver, Vancouver, Canada, ⁷IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, ⁸The Hospital for Sick Children and University of Toronto, Toronto, Canada, ⁹University of Calgary, Calgary, Alberta, Canada, ¹⁰Alberta Children's Hospital/University of Calgary, Calgary, Alberta, Canada, ¹¹University of Toronto/Hospital for Sick Children, Thornhill, Canada, ¹²BC Children's Hospital, Vancouver, British Columbia, Canada, ¹³The Hospital for Sick Children, Toonto, Canada, ¹⁴University of Toronto & The Hospital for Sick Children, Toronto, Ontario, Canada
Background/Purpose: Pain is the most common symptom of Juvenile Idiopathic Arthritis (JIA), a chronic childhood illness that has potentially debilitating effects on health-related quality of…
Abstract Number: 167 • 2020 Pediatric Rheumatology Symposium
Lipidomic Profiles of Synovial Fluid from Patients with Oligoarticular Juvenile Idiopathic Arthritis Naïve to Treatment
Melissa Elder ¹, Luciana Paim marques², Akaluck Thatayatikom ¹, John Bowden ², Bianca da SIlva ² and Juan Aristizabal ², ¹University of Florida, Gainesville, ²University of Florida, Gainesville, Florida
Background/Purpose: Metabolomic and lipidomic pathways serve as key sensors and effectors of genetic, epigenetic, and environmental factors that shape the development and function of the…
Abstract Number: 022 • 2020 Pediatric Rheumatology Symposium
Association of Plasma Metabolomic Profiles with Methotrexate Response in Juvenile Idiopathic Arthritis
Ryan Funk¹ and Mara Becker ², ¹University of Kansas, Leawood, Kansas, ²Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill
Background/Purpose: Despite efforts to identify biomarkers to guide therapy in the treatment of juvenile idiopathic arthritis (JIA), drug therapy remains a trial-and-error process. In the…
Abstract Number: 101 • 2020 Pediatric Rheumatology Symposium
Uveitis Treatment in the CARRA II Registry: Tumor Necrosis Factor-inhibitors and Beyond
Mona Riskalla¹, Fatima Barbar-Smiley ², Michael Shyne ¹ and Melissa Lerman ³, ¹University of Minnesota, Minneapolis, Minnesota, ²Nationwide Children's Hospital, Columbus, Ohio, ³Philadelphia, Pennsylvania
Background/Purpose: Uveitis associated with JIA (JIA-U) is the most common extra-articular complication of JIA. As JIA-U is associated with significant risk of visual loss and…
Abstract Number: 171 • 2020 Pediatric Rheumatology Symposium
Development and Acceptability of an Adolescent Self-management Program for Juvenile Idiopathic Arthritis
Kelsey Chomistek¹, Cheryl Barnabe ², Katie Birnie ³, Julia Brooks ⁴, Tracey Clancy ⁵, Syeda Farwa Naqvi ⁵, Nadia Luca ⁵, Maggie Mercer ⁴, Maria Santana ⁵, Jennifer Stinson ⁶, Aynsley Wennberg ⁴ and Heinrike Schmeling ⁷, ¹Calgary, Alberta, Canada, ²University of Calgary, Calgary, Alberta, Canada, ³Alberta Children's Hospital, Calgary, Canada, ⁴Alberta Children's Hospital, Calgary, Alberta, Canada, ⁵University of Calgary, Calgary, Canada, ⁶University of Toronto & The Hospital for Sick Children, Toronto, Ontario, Canada, ⁷Alberta Children's Hospital/University of Calgary, Calgary, Alberta, Canada
Background/Purpose: Needs assessments have revealed an urgent need for disease information, self-management skills, and peer support for patients with juvenile idiopathic arthritis (JIA). Our aim…
Abstract Number: 029 • 2020 Pediatric Rheumatology Symposium
Comparison of Efficacy Between Triamcinolone Acetonide and Hexacetonide Intra-articular Treatment for Clinical Remission in Juvenile Idiopathic Arthritis
Angela Chun¹, Lutfiyya Muhammad ² and Deirdre De Ranieri ³, ¹Lurie Children's Hospital, Chicago, Iowa, ²Northwestern University Feinberg School of Medicine, Chicago, ³Lurie Children's Hospital, Chicago, Illinois
Background/Purpose: The use of intra-articular corticosteroid (IAC) injections for Juvenile Idiopathic Arthritis (JIA) was extrapolated from its use in adult inflammatory joint diseases to achieve…
Abstract Number: 107 • 2020 Pediatric Rheumatology Symposium
Defining the Prevalence of Depression and Anxiety Symptoms in Adolescents with Juvenile Idiopathic Arthritis
Lydia Li¹, Mehveen Merchant ², Shelina Gordon ³, David Lovas ⁴, Joanne Gillespie ⁴, Adam Huber ⁵, Bianca Lang ⁶, Suzanne Ramsey ⁴ and Elizabeth Stringer ⁴, ¹Dalhousie University, Halifax, Canada, ²Calgary, Canada, ³IWK Health Centre, Halifax, ⁴IWK Health Centre, Halifax, Canada, ⁵IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, ⁶Dalhousie University - Halifax, Halifax, Canada
Background/Purpose: We aimed to evaluate the prevalence of depressive and/or anxiety symptoms in adolescents with juvenile idiopathic arthritis (JIA) and explore the association with demographic…
Abstract Number: 175 • 2020 Pediatric Rheumatology Symposium
Application of Juvenile Idiopathic Arthritis Treatment Guidelines and Factors Associated with Increased Likelihood of Intra-articular Corticosteroid Administration
Erin Balay¹, Jennifer Weiss ², Y. Ingrid Goh ³, Nathan Rubin ⁴ and Danielle Bullock ⁴, ¹University of Minnesota, saint paul, ²Hackensack University Medical Center, Hackensack, ³The Hospital for Sick Children, Toronto, Canada, ⁴University of Minnesota, Minneapolis
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic childhood disease which can result in debilitating arthritis. The 2011 ACR JIA treatment guidelines recommend intra-articular corticosteroid…
Abstract Number: L22 • 2019 ACR/ARP Annual Meeting
Tofacitinib for the Treatment of Polyarticular Course Juvenile Idiopathic Arthritis: Results of a Phase 3 Randomized, Double-blind, Placebo-controlled Withdrawal Study
Hermine Brunner¹, Olga Synoverska ², Tracy Ting ³, Carlos Abud Mendoza ², Alberto Spindler ², Yulia Vyzhga ², Katherine Marzan ³, Vladimir Keltsev ², Irit Tirosh ², Lisa Imundo ³, Rita Jerath ³, Daniel Kingsbury ³, Betul Sozeri ², Sheetal Vora ³, Sampath Prahalad ³, Elena Zholobova ², Yonatan Butbul Aviel ², Vyacheslav Chasnyk ², Melissa Lerman ³, Kabita Nanda ³, Heinrike Schmeling ³, Heather Tory ³, Yosef Uziel ², Diego Oscar Viola ², Holly Posner ⁴, Keith Kanik ⁵, Ann Wouters ⁴, Cheng Chang ⁵, Richard Zhang ⁴, Irina Lazariciu ⁶, Ming-Ann Hsu ⁵, Ricardo Suehiro ⁷, Alberto Martini ², Daniel J. Lovell ³ and Nicolino Ruperto ⁸, ¹PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, ²PRINTO, Istituto Giannina Gaslini, Genova, Italy, ³PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, ⁴Pfizer Inc, New York, New York, ⁵Pfizer Inc, Groton, Connecticut, ⁶IQVIA, Montreal, Quebec, Canada, ⁷Pfizer Inc, Collegeville, Pennsylvania, ⁸PRINTO, Istituto Giannina Gaslini, Genoa, Italy
Background/Purpose: Tofacitinib is an oral JAK inhibitor that is being investigated for JIA. Here we assess the efficacy and safety of tofacitinib in patients (pts)…
Abstract Number: 187 • 2019 ACR/ARP Annual Meeting
Epidemiology of JIA-Associated Uveitis: Environmental Factors and Disease Characteristics of a JIA-Associated Uveitis Cohort
Theresa Hennard ¹, Najima Mwase ², Amy Cassedy ³, Joseph McDonald ⁴, Virginia Utz ⁵ and Sheila Angeles-Han⁶, ¹Division of Rheumatology, Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ²Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, ⁴Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, ⁵Division of Ophthalmology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cinicinnati
Background/Purpose: JIA-associated uveitis (JIA-U) is the most prevalent extra-articular manifestation of JIA and the most common type of uveitis in children. To date, environmental factors…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].